The effect of nutritional therapy after RFA for HCC patients

The effect of nutritional therapy after RFA for HCC patients - Nutritional therapy for HCC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002412

Enrollment

300

Registered

2009-09-01

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All patients with HCC who recieve RFA therapy

Interventions

liver diet aminoleban EN(2 sachets/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Informed consent was obtained 2.Patients can recieve RFA or TACE and conbination therapy 3.Patients has not receive Aminoleban EN before 2 weeks

Exclusion criteria

Exclusion criteria: 1.Patients complicated severe DM 2.Patients receive dialysis 3.Patients experienced adverse events from HCC therapy 4.Patients complicated severe ascites 5.Patients have allergic reaction for milk 6.Patients take nutrional supplements (>=200kcal)

Design outcomes

Primary

Measure	Time frame
The rate of ectopic recurrence of HCC	—

Countries

Japan

Contacts

Public ContactSHUNSUKE NOJIRI

Nagoya City University Hospital division of liver and pancreas

snojiri@med.nagoya-cu.ac.jp52-851-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026